LY4337713

Phase 1Small molecule

Eli Lilly

LY4337713 is one of 9 small molecule programs targeting Ovarian Neoplasms. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian NeoplasmsRecruiting

Ovarian NeoplasmsPhase 1

Recruiting

Competition

Competitive Landscape

11 competitors in Ovarian Neoplasms

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

6 2

Keytruda

Merck & Co.

Phase 3

2 3

Trodelvy

Gilead

Phase 3

1 4

Paraplatin

AAvyxa

Phase 3

3 5

Rescue

Merck & Co.

Phase 3

1 6

Mocertatug Rezetecan

GSK

Phase 3

3 7

Zejula

GGlaxo Dba Glaxosmithkline

Phase 2

1 8

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 1

1 9

LY4337713

Eli Lilly

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2033

Phase 1Recruiting

Ovarian Neoplasms

NCT07213791

Clinical

Trials by Indication[1]

Ovarian Neoplasms1 trial

A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT07213791·241 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LY4337713. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY4337713 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY4337713. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eli Lilly

LY4337713

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2033

Trials by Indication[1]

Ovarian Neoplasms1 trial

References

Drug Info

Quick Facts

Related News